Biotech investors collect a fraction of milestone cash

With pharma's biotech buyouts increasingly light on up-front cash and heavy on milestone payments, investors are collecting less money from M&A deals. Only 24% of milestone money actually changed hands in deals made from January 2005 through December 2009. Report